Skip to content

GRCE

Grace Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.88
−0.53%
Ask drillr

Forward multiples

Based on analyst estimates

P/E forward
—
P/E 2026E
—
P/E 2027E
—
P/E 2028E
1.15x
P/S forward
2.40x

Trailing multiples

Trailing twelve months

P/E TTM
—
PEG TTM
—
Price / book
0.82x
Price / sales
—
Price / cash flow
-3.84x

Enterprise value

Enterprise value
$25.8M
EV / sales
—
EV / EBITDA
-1.00x
EV / EBIT
-1.00x
Market cap
$39.5M

Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026